Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Invimestrocel - Athersys

Next Previous
Drug Profile

Invimestrocel - Athersys

Alternative Names: Allogeneic stem cell therapy - Athersys; AMI MultiStem; HLCM 051; MultiStem; PF-05285401; PF-5285401

Latest Information Update: 28 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Athersys
  • Developer Armed Forces Radiobiology Research Institute; Athersys; Case Western Reserve University; Healios; University of Texas Health Science Center at Houston
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Adult respiratory distress syndrome
  • New Molecular Entity No
  • Available For Licensing Yes - SARS-CoV-2 acute respiratory disease

Highest Development Phases

  • Phase III Ischaemic stroke
  • Phase II/III SARS-CoV-2 acute respiratory disease
  • Phase II Adult respiratory distress syndrome; Graft-versus-host disease; Multiple organ failure; Myocardial infarction
  • Preclinical Acute radiation syndrome
  • No development reported Brain injuries; Heart failure; Multiple sclerosis; Peripheral arterial disorders; Spinal cord injuries; Transplant rejection
  • Discontinued Diabetes mellitus; Mucopolysaccharidosis I; Parkinson's disease; Ulcerative colitis

Most Recent Events

  • 28 Feb 2025 No recent reports of development identified for preclinical development in Heart-failure in USA (IV)
  • 28 Feb 2025 No recent reports of development identified for preclinical development in Peripheral-arterial-disorders in USA (IV)
  • 10 Oct 2023 Athersys suspends a phase III MASTERS-2 trial in Ischaemic stroke in the USA and Taiwan (IV, Infusion) due to company intends to conduct additional data analysis with independent statisticians (NCT03545607)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top